Painful Diabetic Peripheral Neuropathy (PDPN) Clinical Trial
Official title:
A Phase 2a Randomized, Double-Blind, Multicenter, Placebo and Active Controlled Study to Assess Analgesic Efficacy and Safety of ASP3662 in Subjects With Painful Diabetic Peripheral Neuropathy
The purpose of this study is to assess analgesic efficacy of ASP3662 relative to placebo in
subjects with painful diabetic peripheral neuropathy (PDPN) as well as assess the safety and
tolerability of ASP3662 relative to placebo.
The analgesic effect is evaluated by measuring percent responders, change in daily worst pain
score, change in average daily pain score, Patient Global Impression of Change (PGIC) and
Clinical Global Impression of Change (CGIC).
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01478607 -
A Study to Evaluate the Long-term Safety of Repeated QUTENZA Administration for Treatment of Pain Caused by Nerve Damage in Diabetic Patients
|
Phase 3 | |
| Completed |
NCT02065349 -
A Study Into Pain Relief Given by ASP8477 for Peripheral Neuropathic Pain (Either Post-herpetic Neuralgia or Painful Diabetic Peripheral Neuropathy) and Its Safety
|
Phase 2 |